MK-7162
Total Payments
$866,127
Transactions
133
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $30,226 | 11 | 0 |
| 2019 | $248,365 | 50 | 0 |
| 2018 | $560,105 | 63 | 0 |
| 2017 | $27,431 | 9 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $865,227 | 132 | 99.9% |
| Consulting Fee | $900.00 | 1 | 0.1% |
Payments by Type
Research
$865,227
132 transactions
General
$900.00
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 1b Open-label Study of MK-7162 in Combination with PembrolizumabMK-3475 ,- other therapies in Participants with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $829,586 | 0 |
| Phase 1b Open-label Study of MK-7162 in Combination with Pembrolizumab MK-3475 ,- other therapies in Participants with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $30,226 | 0 |
| Phase 1b Open-label Study of MK-7162 in Combination with Pembrolizumab(MK-3475) +/- other therapies in Participants with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $5,415 | 0 |
Top Doctors Receiving Payments for MK-7162
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Santa Monica, CA | $865,227 | 132 |
| , M.D | Diagnostic Radiology | Kendall Park, NJ | $900.00 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $866,127
Product Information
- Type Drug
- Total Payments $866,127
- Total Doctors 1
- Transactions 133
About MK-7162
MK-7162 is a drug associated with $866,127 in payments to 1 healthcare providers, recorded across 133 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $30,226 was paid across 11 transactions to 0 doctors.
The most common payment nature for MK-7162 is "Unspecified" ($865,227, 99.9% of total).
MK-7162 is associated with 3 research studies, including "Phase 1b Open-label Study of MK-7162 in Combination with PembrolizumabMK-3475 ,- other therapies in Participants with Advanced Solid Tumors" ($829,586).